Tepkinly is a cancer medicine used to treat adults with blood cancers called diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), in patients whose cancer has returned (relapsed) or stopped responding (refractory) after at least two previous treatments. Tepkinly contains the active substance epcoritamab.
Therapeutic Indication
### Therapeutic indication Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Therapeutic Area (MeSH)
ATC Code
L01FX27
ATC Item
epcoritamab
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| epcoritamab | N/A | 艾可瑞妥单抗 |
EMA Name
Tepkinly
Medicine Name
Tepkinly
Aliases
N/A
